Skip to main content
Kent Academic Repository

Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

Hale, Anthony S., Azorin, Jean-Michel, Kasper, Siegfried, Maier, Wolfgang, Syvalahti, Erkka, Van der Burght, Michael, Sloth-Nielsen, Mogens, Wehnert, Allan (2000) Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial. International Journal of Psychiatry in Clinical Practice, 4 (1). pp. 47-54. ISSN 1365-1501. (doi:10.1080/13651500052048758) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:16179)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL:
https://doi.org/10.1080/13651500052048758

Abstract

OBJECT: The objective of this double-blind, multicentre study was to evaluate four noses of sertindole and haloperidol 10 mg. METHOD: The 617 schizophrenic patients were randomized to receive sertindole 8, 16, 20 or 24 mg/day or haloperidol 10 mg/day. Patients were assessed for extrapyramidal symptoms (EPS) using the Simpson-Angus Scale (SAS) and Barnes Akathisia Scale (BAS), and for movement disorders using the Abnormal Involuntary Movement Scale (AIMS). RESULTS: Patients receiving haloperidol experienced significantly more EPS than patients receiving sertindole, supporting observations mane in. previous studies. The incidence of adverse events was similar for all noses of sertindole. SAS and BAS scores were significantly worse in the haloperidol,group than in. the sertindole groups. There were significantly greater increases in mean QT(c) interval in the sertindole groups than in the haloperidol group. Sertindole did not cause sedation. CONCLUSIONS: Sertindole is well tolerated and does not cause the debilitating EPS associated with traditional antipsychotic drugs.

Item Type: Article
DOI/Identification number: 10.1080/13651500052048758
Additional information: Alternate email: PROFASHALE@aol.com
Uncontrolled keywords: antipsychotic agents; phase III clinical trial; sertindole; extrapyramidal symptoms; schizophrenia
Subjects: B Philosophy. Psychology. Religion > BF Psychology
Divisions: Divisions > Division of Human and Social Sciences > School of Psychology
Depositing User: O.O. Odanye
Date Deposited: 01 May 2009 00:35 UTC
Last Modified: 09 Mar 2023 11:30 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/16179 (The current URI for this page, for reference purposes)

University of Kent Author Information

Hale, Anthony S..

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.